Compared to Estimates, Inspire (INSP) Q2 Earnings: A Look at Key Metrics

Inspire Medical Systems (INSP) reported strong Q2 2025 financial results, with EPS of $0.45 significantly exceeding consensus by 104.55% and revenue of $217.09 million slightly beating estimates by 0.95%. While U.S. geographic revenue grew 10.3% and international revenue surged 23% year-over-year, the company notably missed analyst projections for both total and new U.S. sales territories. Despite the headline earnings beat, INSP shares have underperformed the S&P 500 over the past month.

Analysis

Inspire Medical Systems (INSP) reported mixed results for Q2 2025, characterized by a significant bottom-line beat but concerning underlying growth metrics. Revenue grew 10.8% year-over-year to $217.09 million, narrowly surpassing the consensus estimate by 0.95%. The standout figure was the earnings per share of $0.45, which was a 104.55% positive surprise over the $0.22 estimate and a substantial increase from the $0.32 recorded in the same quarter last year. However, a closer look at operational data reveals potential headwinds; the company significantly missed analyst targets for U.S. sales territory expansion, adding only 5 new territories against an expectation of 13, and reaching a total of 348 versus an estimated 356. While U.S. revenue grew 10.3% to $207.15 million, slightly ahead of projections, the international segment was a bright spot, with revenue surging 23% to $9.94 million, well above its estimate. The market's reaction appears muted, with the stock's -1.9% return over the past month underperforming the S&P 500, suggesting investors are weighing the impressive profitability against the slowdown in domestic expansion.

Key Decisions for Investors

• Investors should look beyond the headline EPS beat and critically assess the significant miss in new U.S. sales territory additions, as this is a key leading indicator for future domestic revenue growth.
• The strong outperformance of the international revenue segment, which grew 23% year-over-year, warrants close monitoring as it could become a more critical growth driver if U.S. expansion continues to moderate.
• Given the stock's recent underperformance despite the earnings beat, it may be prudent to maintain a neutral stance, as the market appears to be pricing in concerns about slowing growth, aligning with the Zacks Rank #3 (Hold) designation.